[Monoclonal antibody therapy in hematological malignancies].
نویسنده
چکیده
What do you do to start reading monoclonal antibody therapy in hematologic malignancies? Searching the book that you love to read first or find an interesting book that will make you want to read? Everybody has difference with their reason of reading a book. Actuary, reading habit must be from earlier. Many people may be love to read, but not a book. It's not fault. Someone will be bored to open the thick book with small words to read. In more, this is the real condition. So do happen probably with this monoclonal antibody therapy in hematologic malignancies.
منابع مشابه
HDV+HBV hepatitis reactivation due to immunossuppressive therapy for hematological malignancies – an increasingly complex challenge
Background Hepatitis B virus reactivation (HBV-R) is becoming an increasingly concerning issue as monoclonal antibody therapy has become widely used for chronic lymphoproliferations. HBV-R can also occur in HBsAg negative patients who have only HBcAb positive (occult HBV infection). We present a non-consecutive HBV-R case series report. Our series consisted of both HBsAg positive patients and p...
متن کاملDetermination of Serologic and Molecular Prevalence of Hepatitis Type B, C, and G Infections in Patients with Hematological Malignancy in the South of Fars Province, Iran
Background & Objectives: Hepatitis type G virus (HGV) is a flavivirus with RNA genome which has high nucleotide and amino acid similarity with HCV. HGV can infect blood lymphocytes for long period and may have role in inducing or complicating the clinical outcomes in patients with hematological malignancies. Therefore in this study the prevalence of HGV, HCV, and HBV infections were evaluated i...
متن کاملChallenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy
Patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are prone to present with antibody production deficits associated with recurrent or severe bacterial infections that might benefit from human immunoglobulin (Ig) (IVIg/SCIg) replacement therapy. However, the original IVIg trial data were done before modern therapies were available, and the current indications do not take...
متن کاملMonoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
Today, monoclonal antibodies (mAbs) are a widespread and necessary tool for biomedical science. In the hematological cancer field, since rituximab became the first mAb approved by the Food and Drug Administration for the treatment of B-cell malignancies, a number of effective mAbs targeting lineage-specific antigens (LSAs) have been successfully developed. Non-LSAs (NLSAs) are molecules that ar...
متن کاملMonoclonal antibodies in hematological malignancies: past, present and future.
Much progress has been made during the last few decades in the treatment of hematological malignancies. Monoclonal antibodies (MoAbs) represent a major advance toward a targeted therapy that can dramatically improve the antitumor effect with a substantial reduction of toxicity derived from therapy. Unlike many small molecules, MoAbs offer unique target specificity. Several MoAbs are now in clin...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Nihon rinsho. Japanese journal of clinical medicine
دوره 70 Suppl 2 شماره
صفحات -
تاریخ انتشار 2012